Cargando…

Evaluation of the Developmental Toxicity of Vedolizumab, an α(4)β(7) Receptor Antagonist, in Rabbit and Nonhuman Primate

Vedolizumab, a humanized monoclonal antibody approved for the treatment of adults with moderately to severely active ulcerative colitis or Crohn disease, targets α(4)β(7) integrin and selectively blocks gut-specific lymphocyte trafficking. The potential effects of vedolizumab on development were ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Crawford, David, Friedman, Mitchell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749749/
https://www.ncbi.nlm.nih.gov/pubmed/31364424
http://dx.doi.org/10.1177/1091581819864105